Amplia Therapeutics Ltd (ASX: ATX) has announced a significant milestone in its Phase 2a ACCENT trial for advanced pancreatic cancer. The trial, which examines the efficacy of narmafotinib combined with standard chemotherapy, has reported a confirmed partial response from another patient. This brings the total number of responders in the first cohort to four.
To proceed to the second cohort, at least six out of 26 patients in the first group need to demonstrate a partial or complete response. With three patients already meeting this criterion, the recent confirmation of another partial response means only two more are required. A confirmed partial response is defined by a 30% reduction in tumor size without new lesions, maintained for two months. The positive results align with previous clinical and preclinical findings, and ASX healthcare stock Amplia remains on track to complete the interim analysis by the end of the quarter.
Compumedics Ltd (ASX: CMP) has secured a €0.6 million ($1 million) order for its advanced Okti neurological wireless amplifier. This order will be used by two leading epilepsy hospitals in Berlin and underscores the strong performance of Compumedics' European business, which saw sales surge by 63% to $7.6 million in FY24.
The Okti amplifier, which offers high-definition portable EEG capabilities with up to 128 channels, has been selected by prominent institutions such as Charité – Universitätsmedizin Berlin. This order follows a rigorous two-year selection process and highlights Compumedics' growing influence in the pediatric neurology field across Europe. The European market for Compumedics' products is estimated to be worth up to EUR 300 million annually, with a projected growth rate of 10%.
EZZ Life Science Ltd (ASX: EZZ) has expanded its product range with the introduction of four new functional food items. This marks EZZ’s entry into the functional foods sector, aimed at addressing nutritional needs for both children and adults.
The new products include EZZ Multi Vitamins Milk Powder and EZZ KidzSure Formulated Nutrition Powder for children aged three and up, as well as EZZ Lactoferrin Complex Powder for the same age group. For adults, the company is launching EZZ VitalSure Formulated Nutrition Powder. Manufactured in New Zealand, these products are designed to provide essential vitamins, minerals, and nutrients.
EZZ plans to leverage its omnichannel distribution network to introduce these products, with a focus on mainland China. This move taps into the rapidly growing functional foods market in the Asia-Pacific region, valued at US$130.85 billion and expected to grow at a rate of 10.46% annually from 2024 to 2032. Glenn Cross, Chair of EZZ, expressed enthusiasm about the new product range, highlighting the increasing demand for high-quality nutrition products.
These recent developments from Amplia Therapeutics, Compumedics, and EZZ Life Science illustrate notable advancements and opportunities within their respective fields.